ChristiaanWSchiepersMDPhD
Nuclear Medicine • Los Angeles, CAProfessor, Molecular & Medical Pharmacology, University of California Los Angeles David Geffen SOM
Are you Dr. Schiepers?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 43 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 UCLA Medical Plz
Suite B114
Los Angeles, CA 90095Phone+1 310-983-1439Fax+1 310-206-4899
Summary
- Dr. Christiaan Schiepers, MD is a board certified nuclear medicine physician in Los Angeles, California. He is currently licensed to practice medicine in California. He is affiliated with Ronald Reagan UCLA Medical Center and UCLA Medical Center-Santa Monica.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Radiology-Diagnostic, 1989 - 1990
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Nuclear Medicine, 1987 - 1989
Albany Medical CenterFellowship, Cardiovascular Disease, 1986 - 1987- Albany Medical CenterResidency, Internal Medicine, 1984 - 1986
Utrecht University Faculty of MedicineClass of 1982
Certifications & Licensure
CA State Medical License 1988 - 2026- American Board of Nuclear Medicine Nuclear Medicine
Clinical Trials
- The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases Start of enrollment: 2008 May 01
- The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases Start of enrollment: 2007 Nov 01
- 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
Publications & Presentations
PubMed
- 9 citationsQuantitative bone scan lesion area as an early surrogate outcome measure indicative of overall survival in metastatic prostate cancer.Matthew S. Brown, Grace Kim, Gregory H. Chu, Bharath Ramakrishna, Martin Allen-Auerbach
Journal of Medical Imaging. 2018-01-11 - 24 citationsMost of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented.Jeremie Calais, Johannes Czernin, Matthias Eiber, Wolfgang P. Fendler, Jeannine Gartmann
Journal of Nuclear Medicine. 2017-05-04 - 17 citationsHuman Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway.Martin Barrio, Claudio Spick, Caius G. Radu, Michael Lassmann, Uta Eberlein
Journal of Nuclear Medicine. 2017-03-01
Press Mentions
Newly Developed PSG Score Improves Patient Selection for PSMA Radiopharmaceutical TherapyApril 20th, 2023
